Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences
Rhea-AI Summary
Beam Therapeutics (Nasdaq: BEAM), a biotechnology company specializing in precision genetic medicines through base editing, has announced its management's upcoming participation in three major investor conferences in March 2025:
• The TD Cowen 45th Annual Health Care Conference on March 3 at 1:50 p.m. ET
• The Leerink Partners Global Biopharma Conference on March 10 at 1:40 p.m. ET
• The Barclays Global Healthcare Conference on March 11 at 3:30 p.m. ET
The company will participate in fireside chats at each event. Live webcasts will be accessible through Beam's investor website section at www.beamtx.com and will remain archived for 60 days after the presentations.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, BEAM gained 1.18%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in fireside chats at the following upcoming investor conferences:
- TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 1:50 p.m. ET
- Leerink Partners Global Biopharma Conference on Monday, March 10, 2025, at 1:40 p.m. ET
- Barclays Global Healthcare Conference on Tuesday, March 11, 2025, at 3:30 p.m. ET
The live webcasts will be available in the investor section of the company's website at www.beamtx.com and will be archived for 60 days following the presentation.
About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.
Contact:
Holly Manning
Beam Therapeutics
hmanning@beamtx.com
FAQ
When is Beam Therapeutics (BEAM) presenting at the TD Cowen Healthcare Conference in March 2025?
How long will BEAM's March 2025 conference webcasts be available for viewing?
Which investor conferences is BEAM participating in during March 2025?
Where can investors access BEAM's March 2025 conference presentations?
What type of presentation format will BEAM use at the March 2025 investor conferences?
